CTRI/2022/04/042009已完成2 期
A double-blind, randomized, placebo-controlled efficacy trial of individualized homoeopathic medicines in treatment of nocturnal enuresis
D N De Homoeopathic Medical College and Hospital0 个研究点目标入组 140 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients suffering from nocturnal enuresis since at least 3 months
- •2. Age 5-18 years
- •3. Patients of either sex.
- •4. Literate patients; ability to read English, Hindi and/or Bengali
- •5. Providing with written informed consent/assent
排除标准
- •1. Patients having any anatomical and/or surgical changes leading to enuresis
- •2. Patients taking any systemic antibiotics in the past one month.
- •3. Vulnerable population – unconscious, ambulatory, too sick for consultation, differently abled, terminally or critically ill patients, mentally incompetent people
- •4. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure
- •5. Patients with a habit of tobacco chewing and /or smoking, alcoholism and/or any form (s) of substance abuse and/or dependence
- •6. Self-reported immune-compromised state
- •7. Already undergoing homeopathic treatment for chronic disease within last 6 months
研究者
相似试验
招募中
2 期
Homeopathic treatment of geriatric depressioCTRI/2017/03/008078MBHM College Hospital MHM College Hospital The CHM College Hospital
进行中（未招募）
不适用
A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizuresEUCTR2006-000987-10-FICB S.A.130
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
已完成
2 期
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic urticaria10002426NL-OMON30213Barrier Therapeutics16
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-CZBarrier Therapeutics nv48